133 related articles for article (PubMed ID: 6605114)
1. [Effect of human lymphoblast interferon in adult T-cell leukemia and non-Hodgkin's lymphoma].
Kamihira S; Soda H; Kinoshita K; Ichimaru M
Gan To Kagaku Ryoho; 1983 Oct; 10(10):2188-93. PubMed ID: 6605114
[TBL] [Abstract][Full Text] [Related]
2. [Clinical trial of human lymphoblastoid interferon on advanced malignancy].
Usui N; Ogawa M; Inagaki J; Horikoshi N; Inoue K; Miyamoto H; Ikeda K; Nakada H; Adachi K; Okada Y
Gan To Kagaku Ryoho; 1983 Nov; 10(11):2324-9. PubMed ID: 6357102
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of leukemias and lymphomas with interferons: III. Trial treatment of meningeal localizations of acute leukemia and non-Hodgkin's lymphomas with beta interferon administered by the intrathecal route].
Misset JL; Mathé G; Gastiaburu J; Goutner A; Dorval TI; Gouveia J; Hayat M; Jasmin C; Schwarzenberg L; Machover D; Ribaud P; de Vassal F; Horoszewicz JP
Biomed Pharmacother; 1982; 36(3):167-70. PubMed ID: 6758874
[TBL] [Abstract][Full Text] [Related]
5. [Clinical study on the effect of natural alpha-interferon (HLBI) in the treatment of adult T-cell leukemia].
Ichimaru M; Kamihira S; Moriuchi Y; Kuraishi Y; Usui N; Toki H; Okabe K; Niho Y; Shibuya T; Umei T
Gan To Kagaku Ryoho; 1988 Oct; 15(10):2975-81. PubMed ID: 3052302
[TBL] [Abstract][Full Text] [Related]
6. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
7. [Effect of topical injections of native alpha-interferon (HLBI) in the treatment of skin lesions of adult T cell leukemia: report of a case].
Sugie Y; Hayashi S; Shibuya T; Otsuka T; Okamura T; Harada M; Niho Y
Rinsho Ketsueki; 1990 Apr; 31(4):497-501. PubMed ID: 2381068
[TBL] [Abstract][Full Text] [Related]
8. Time-dependent cytotoxic action of human recombinant alpha-interferon (Ro22-8181) in vitro and the sensitivity of various cultured leukemia and lymphoma cell lines to it.
Shibata T; Shimada Y; Shimoyama M
Jpn J Clin Oncol; 1985 Mar; 15(1):67-75. PubMed ID: 3981816
[TBL] [Abstract][Full Text] [Related]
9. [A cooperative phase I-II study of HLBI in patients with malignant tumors].
Kimura K
Gan To Kagaku Ryoho; 1984 Jun; 11(6):1324-31. PubMed ID: 6329104
[TBL] [Abstract][Full Text] [Related]
10. Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
Zinzani PL; Levrero MG; Lauria F; Rondelli D; Zaja F; Russo D; Fanin R; De Rossi G; Mauro FR; Bendandi M; Gozzetti A; Dianzani F; Mandelli F; Tura S
Haematologica; 1994; 79(1):55-60. PubMed ID: 15378949
[TBL] [Abstract][Full Text] [Related]
11. [Clinical study on the effect of human lymphoblastoid interferon in multiple myeloma].
Takeyama H; Yano K; Kataoka T; Yamamoto M; Emi N; Kodera Y; Kawashima K; Ohno R; Yokomaku S; Kobayashi M
Gan To Kagaku Ryoho; 1983 Sep; 10(9):2043-8. PubMed ID: 6614939
[TBL] [Abstract][Full Text] [Related]
12. [Introduction of natural interferon-alpha "Sumiferon"].
Tsukagoshi S
Gan To Kagaku Ryoho; 1987 Sep; 14(9):2800-3. PubMed ID: 3631977
[TBL] [Abstract][Full Text] [Related]
13. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group.
Santini G; Coser P; Congiu AM; Salvagno L; De Souza C; Sertoli MR; Olivieri A; Chisesi T; Rubagotti A; Truini M; Contu A; Porcellini A; Zambaldi G; Nati S; Marino G; Rizzoli V
Haematologica; 2000 Feb; 85(2):160-6. PubMed ID: 10681723
[TBL] [Abstract][Full Text] [Related]
14. [Clinical effects of human lymphoblastoid interferon in patients with hematologic neoplasms].
Oda Y; Irie S; Inagaki M; Fukumoto M; Ueda I; Ohmoto E; Fujimoto S; Endo Y; Watanabe S; Lai M; Takahashi I; Kimura I; Ishii H; Sezaki T
Gan To Kagaku Ryoho; 1983 May; 10(5):1313-9. PubMed ID: 6575725
[TBL] [Abstract][Full Text] [Related]
15. [Phase II study of recombinant leukocyte A interferon (Ro 22-8181) in hematological malignancies].
Gan To Kagaku Ryoho; 1985 Apr; 12(4):928-35. PubMed ID: 3885864
[TBL] [Abstract][Full Text] [Related]
16. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of non-Hodgkin's lymphoma with NK-631 (peplomycin)--with special reference to the effect on T and non-T cell lymphomas].
Kamihira S; Jinnai I; Kinoshita K; Ichimaru M
Gan To Kagaku Ryoho; 1982 Feb; 9(2):289-92. PubMed ID: 6191697
[TBL] [Abstract][Full Text] [Related]
18. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
19. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ
Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720
[TBL] [Abstract][Full Text] [Related]
20. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
Carella AM; Lerma E; Dejana A; Corsetti MT; Celesti L; Bruni R; Benvenuto F; Figari O; Parodi C; Carlier P; Florio G; Lercari G; Valbonesi M; Casarino L; De Stefano F; Geniram A; Venturino M; Tedeschi L; Palmieri G; Piaggio G; Podestà M; Frassoni F; Van Lint MT; Marmont AM; Bacigalupo A
Haematologica; 1998 Oct; 83(10):904-9. PubMed ID: 9830799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
